Today, breast cancer (BC) is the most commonly diagnosed cancer in women. HER2-positive BC is one of the BC subtypes that is characterized by the presence/absence of estrogen and progesterone receptors and, most of all, overexpression of the human epidermal growth factor receptor2 (HER2), determining both the disease prognosis and treatment strategy. Unfortunately, actual therapy of early HER2-positive cancer,r considering all the "targets" does not fully achieve all the goals, the main of which are a pathological complete response and decreased incidence of cardiac complications after the treatment. This determines the relevance of searching for all the possible significant predictive factors of response to the drug therapy, reduced risk of cardiac complications and pharmacoeconomical justification of the therapy regimens. A presented literature review identifies the most important and relevant issues associated with neoadjuvant drug therapy of luminal/non-luminal HER2-positive BC along with possible solutions.

Lyubov Krivolapova is the Head of the Department of Antitumor Drug Therapy with Day Hospital at the Federal State Budgetary Scientific Institution "Russian Scientific Center of Surgery named after Academician B.V. Petrovsky" in Moscow. She is currently working on her PhD thesis on the treatment of breast cancer. She has published 5 articles, including one in a foreign journal